Skip to main content
Clinical Trials/NCT01716845
NCT01716845
Completed
Not Applicable

SynapDx Autism Spectrum Disorder Gene Expression Analysis Study

SynapDx1 site in 1 country660 target enrollmentOctober 2012
ConditionsAutism

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autism
Sponsor
SynapDx
Enrollment
660
Locations
1
Primary Endpoint
RNA gene expression in peripheral blood
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This study will prospectively enroll approximately 660 children, at least 18 months and less than 5 years of age, who have been referred to a pediatric developmental evaluation centers. Enrolled children will have blood drawn for RNA gene expression analysis and undergo a clinical evaluation to determine the presence or absence of a diagnosis of ASD.

The sequential co-primary objectives of this study are:

  • To develop an algorithm to classify blood RNA gene expression patterns to maximize agreement between the classification and a clinical assessment of presence or absence of Autism Spectrum Disorders (ASD).
  • To prospectively assess the clinical sensitivity and specificity of the blood RNA gene expression classification algorithm (the SDX-002 test) in children referred to a developmental evaluation clinic for a possible developmental disorder.
Registry
clinicaltrials.gov
Start Date
October 2012
End Date
December 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
SynapDx
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Referred to a developmental evaluation centers for evaluation of a possible developmental disorder, other than isolated motor problems.
  • Age \>= 18 months and \< 5 years.
  • Parent/legal guardian has been informed about the study and has signed an informed consent form.

Exclusion Criteria

  • Prior reliable diagnosis of Autism Spectrum Disorder (i.e. prior evaluation by a multi-disciplinary team has already reliably established Autism Spectrum Disorder diagnosis).
  • Unable or unwilling to complete study procedures

Outcomes

Primary Outcomes

RNA gene expression in peripheral blood

Time Frame: within 30 days of collection

Study Sites (1)

Loading locations...

Similar Trials